Back

Safety and tolerability of a first in class chymase inhibitor in clinically stable patients with left-ventricular dysfunction after myocardial infarction

26 May 2018 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 4 - Chronic Heart Failure – Pathophysiology and Mechanisms Pathophysiology and Mechanisms HFA Premium Access Heart Failure 2018

About the speaker

Photo
Professor Michele Senni

Papa Giovanni XXIII Hospital, Bergamo (Italy)

25 More presentations in this session

Presentation thumbnail
The relations between pro- and anti-inflammatory cytokines contractile ability of the myocardium in patients with coronary artery disease
Presentation thumbnail
Predictors of galectin-3 in patients with heart failure and reduced ejection fraction
Doctor I. Alexanian (Athens, GR)
Presentation thumbnail
The role of Response-to-Diuretic in predicting prognosis in discharged heart failure patients after an acute decompensation.
Doctor M. Feola (Mondovi, IT)
Abstract
Presentation thumbnail
Mobile cardiopaging in toxic cardiomyopathy diagnostics in cancer patients
Professor N. Lyamina (Moscow, RU)
Abstract
Presentation thumbnail
Use of sacubitril valsartan in heart failure due to post-chemotherapy symptomatic ventricular dysfunction
Doctor V. Gregorietti (Buenos Aires, AR)
Abstract

Access the full session

Session thumbnail
Poster Session 4 - Chronic Heart Failure – Pathophysiology and Mechanisms

The Event

Event poster

Heart Failure 2018

26 May - 29 May 2018
You may be interested in
thumbnail
Congress Presentation
Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: a phenomics approach.
thumbnail
Congress Session
Bridging gaps in heart failure care: primary care trends, exercise, kidney function, and global health perspectives
thumbnail
Congress Session
Chronic kidney disease and heart failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources